SUBSCRIBE
SUBSCRIBE

Neil Versel

Pictured: AI robot holding biopharma-related items in hands
The Many Ways Biopharma Can Use Artificial Intelligence, Including Generative AI
Applications of the technology range from data collection to drug design to raising the alarm on product safety, but its adoption is also creating some anxiety.
May 14, 2024
 · 
4 min read
 · 
Neil Versel
Pictured: Robot hand holding microscope, pill bottles and DNA
Drug Development
Generative AI Finds Its Footing in Drug Development
Since the 2022 launch of ChatGPT, biopharma has poured money into this new form of artificial intelligence, but companies remain cautious with unproven technology.
May 3, 2024
 · 
6 min read
 · 
Neil Versel
Pictured: Collage of the U.S. Capitol, pills, money and justice statue
Policy
Drug Companies, VCs Rethink R&D Strategies as IRA Stands Strong in Court
This week’s legal losses by J&J and BMS reinforce the notion that Medicare drug price negotiation is here to stay, and investors continue to favor biologics over small molecules.
April 30, 2024
 · 
6 min read
 · 
Neil Versel
Pictured: Judicial gavel and scales of justice
Policy
J&J, BMS Lose Challenges to Medicare Drug Price Negotiation Program
A federal court issued a summary judgment saying that the IRA provision does not represent an unconstitutional taking of property but did not rule on suits by Novartis and Novo Nordisk.
April 30, 2024
 · 
2 min read
 · 
Neil Versel
Pictured: Illustration depicting large layoffs/iSt
Business
Tessera Cuts Dozens of Jobs Following Positive Preclinical Results
The genetic engineering startup, recently honored by BioSpace readers for its work environment, is downsizing as it seeks to launch its first clinical trials.
April 26, 2024
 · 
1 min read
 · 
Neil Versel
Robert Hariri/Celularity photo
Business
Robert Hariri: Developing Cost-Effective Cell Therapies From Placentas
The Celularity CEO and founder tells BioSpace he believes that placenta-derived cells are the future of stem cell therapies to fight autoimmune disease, cancer, even aging.
April 24, 2024
 · 
5 min read
 · 
Neil Versel
Courtesy Jeremy Moeller/Getty Images
Business
BMS Initiates First Round of Layoffs in New Jersey
This is the first round in a series of cuts that will cost 75 people their jobs this year, according to a WARN notice. Employees in other states are affected as well.
April 23, 2024
 · 
1 min read
 · 
Neil Versel
U.S. and Chinese flags in concrete, broken in the middle
Business
BMS-Cellares CAR-T Pact Highlights U.S.-China Biopharma Tensions
While Bristol Myers Squibb did not explicitly mention China as the company expands and diversifies its manufacturing capacity, Cellares said the BIOSECURE Act would be a boon to its own growth.
April 23, 2024
 · 
3 min read
 · 
Neil Versel
Drug Delivery
Deep Dive: Drug Price Reform
In this deep dive, BioSpace takes a closer look at the drug price crisis in the U.S. As President Joe Biden and former President Donald Trump gear up for a rematch in the 2024 election, we explore how federal reforms to lower costs could be leveraged on the campaign trail.
April 18, 2024
 · 
4 min read
 · 
Neil Versel
Pictured: Abstract collage of money, pills, prostate cancer cells and signing a contract
Arvinas Strikes Deals With Pfizer, Novartis to Compete in Protein Degrader Space
As its lead oral targeted protein degrader moves through Phase III in partnership with Pfizer, Arvinas signs a licensing deal handing over all rights and responsibilities to Novartis.
April 17, 2024
 · 
4 min read
 · 
Neil Versel
Pictured: Shell game with business executives
Business
C-Suite Shuffle: Bayer Continues Leadership Shakeup with Hires at Subsidiaries
Read the latest overview of people coming and going from executive positions at biopharma companies covered by BioSpace.
April 16, 2024
 · 
2 min read
 · 
Neil Versel
Pictured: Hands exchanging money for medical science objects
Top Q1 Series A Investments Highlight VC Rebound in Biopharma
Inflammatory disease–focused Mirador Therapeutics landed the largest early-stage VC investment in biopharma last quarter, as more companies are securing $150 million or more.
April 12, 2024
 · 
4 min read
 · 
Neil Versel
Pictured: Abstract handshake
Deals
7 Billion-Dollar Oncology M&As from Q1
AbbVie’s $10.1 billion takeover of ImmunoGen paces the cancer sector in early 2024, as ADCs and radiopharmaceuticals remain hot.
April 9, 2024
 · 
4 min read
 · 
Neil Versel
Pictured: Pharmacist giving over-the-counter birth control pills
Birth Control Market Evolves as OTC Opill Hits US Stores
Thousands of retail outlets are now receiving shipments of the first over-the-counter birth control pill approved in the U.S., but effects on the overall contraception market are unclear.
April 8, 2024
 · 
4 min read
 · 
Neil Versel
Pictured: Professionals standing around a conference room networking
AstraZeneca, BMS, Pfizer Among Big Pharma to Present at Inaugural AACR Event
The American Association for Cancer Research has invited drug developers and investors to intermingle with the academics who typically attend its annual conference.
April 4, 2024
 · 
3 min read
 · 
Neil Versel
Load More